Quarterly report · Q3
2160.TEDINET S100PN1P
Period2022-01-01 → 2022-09-30
Filed2022-11-14
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 62
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥12.8bn | 2022-01-01 → 2022-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥4.6bn | 2022-07-01 → 2022-09-30d | Cons. | Revenue IFRS |
| Revenue | ¥12.7bn | 2021-01-01 → 2021-12-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥9.5bn | 2021-01-01 → 2021-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥3.1bn | 2021-07-01 → 2021-09-30d | Cons. | Revenue IFRS |
| Operating income | ¥1.5bn | 2022-01-01 → 2022-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥490m | 2022-07-01 → 2022-09-30d | Cons. | Operating profit loss IFRS |
| Operating income | ¥2.0bn | 2021-01-01 → 2021-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥505m | 2021-07-01 → 2021-09-30d | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥1.2bn | 2022-01-01 → 2022-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥433m | 2022-07-01 → 2022-09-30d | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥1.1bn | 2021-01-01 → 2021-12-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥1.6bn | 2021-01-01 → 2021-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥371m | 2021-07-01 → 2021-09-30d | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥1.1bn | 2022-01-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥400m | 2022-07-01 → 2022-09-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥1.1bn | 2021-01-01 → 2021-12-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥1.3bn | 2021-01-01 → 2021-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥353m | 2021-07-01 → 2021-09-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥324m | 2022-01-01 → 2022-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥126m | 2022-07-01 → 2022-09-30d | Cons. | Profit loss IFRS |
| Net income | ¥55m | 2021-01-01 → 2021-12-31 | Cons. | Profit loss IFRS (5-year summary) |
| Net income | ¥875m | 2021-01-01 → 2021-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥130m | 2021-07-01 → 2021-09-30d | Cons. | Profit loss IFRS |
| Total assets | ¥36.5bn | at 2022-09-30 | Cons. | Assets IFRS |
| Total assets | ¥30.3bn | at 2021-12-31 | Cons. | Assets IFRS |
| Total assets | ¥29.8bn | at 2021-09-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥14.4bn | at 2022-09-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥11.0bn | at 2021-12-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥22.0bn | at 2022-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥19.3bn | at 2021-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥19.4bn | at 2021-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥12.8bn | at 2020-12-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥22.9bn | at 2022-09-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥18.9bn | at 2021-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥18.5bn | at 2021-09-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥12.7bn | at 2022-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥14.4bn | at 2021-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥13.9bn | at 2021-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥10.3bn | at 2020-12-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | −¥163m | 2022-01-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥552m | 2021-01-01 → 2021-12-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥755m | 2021-01-01 → 2021-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥2.9bn | 2022-01-01 → 2022-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥261m | 2021-01-01 → 2021-12-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥884m | 2021-01-01 → 2021-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥299m | 2022-01-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥2.9bn | 2021-01-01 → 2021-12-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | ¥3.2bn | 2021-01-01 → 2021-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥22.67 | 2022-01-01 → 2022-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥8.42 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥22.72 | 2021-01-01 → 2021-12-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥27.69 | 2021-01-01 → 2021-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥7.44 | 2021-07-01 → 2021-09-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥22.46 | 2022-01-01 → 2022-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥8.28 | 2022-07-01 → 2022-09-30d | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥22.08 | 2021-01-01 → 2021-12-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥26.87 | 2021-01-01 → 2021-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥7.32 | 2021-07-01 → 2021-09-30d | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 62.8% | at 2022-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 62.3% | at 2021-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 62.1% | at 2021-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 26
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-01-01 → 2022-09-30 | −¥38m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-01-01 → 2022-09-30 | −¥38m |
| jpcrp040300-q3r_E05712-000Medical Devicereportable segment | revenue | 2022-01-01 → 2022-09-30 | ¥1.8bn |
| jpcrp040300-q3r_E05712-000Medical Devicereportable segment | revenue external | 2022-01-01 → 2022-09-30 | ¥1.7bn |
| jpcrp040300-q3r_E05712-000Medical Devicereportable segment | revenue intersegment | 2022-01-01 → 2022-09-30 | ¥38m |
| jpcrp040300-q3r_E05712-000Medical Devicereportable segment | segment profit | 2022-01-01 → 2022-09-30 | ¥699m |
| jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segment | revenue | 2022-01-01 → 2022-09-30 | ¥11.0bn |
| jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segment | revenue external | 2022-01-01 → 2022-09-30 | ¥11.0bn |
| jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segment | segment profit | 2022-01-01 → 2022-09-30 | ¥796m |
| —segment total | revenue | 2022-01-01 → 2022-09-30 | ¥12.8bn |
| —segment total | revenue external | 2022-01-01 → 2022-09-30 | ¥12.8bn |
| —segment total | revenue intersegment | 2022-01-01 → 2022-09-30 | ¥38m |
| —segment total | segment profit | 2022-01-01 → 2022-09-30 | ¥1.5bn |
| Reconciling Itemsreconciling | revenue | 2021-01-01 → 2021-09-30 | −¥35m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-01-01 → 2021-09-30 | −¥35m |
| jpcrp040300-q3r_E05712-000Medical Devicereportable segment | revenue | 2021-01-01 → 2021-09-30 | ¥1.5bn |
| jpcrp040300-q3r_E05712-000Medical Devicereportable segment | revenue external | 2021-01-01 → 2021-09-30 | ¥1.5bn |
| jpcrp040300-q3r_E05712-000Medical Devicereportable segment | revenue intersegment | 2021-01-01 → 2021-09-30 | ¥35m |
| jpcrp040300-q3r_E05712-000Medical Devicereportable segment | segment profit | 2021-01-01 → 2021-09-30 | ¥547m |
| jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segment | revenue | 2021-01-01 → 2021-09-30 | ¥8.1bn |
| jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segment | revenue external | 2021-01-01 → 2021-09-30 | ¥8.1bn |
| jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segment | segment profit | 2021-01-01 → 2021-09-30 | ¥1.4bn |
| —segment total | revenue | 2021-01-01 → 2021-09-30 | ¥9.6bn |
| —segment total | revenue external | 2021-01-01 → 2021-09-30 | ¥9.5bn |
| —segment total | revenue intersegment | 2021-01-01 → 2021-09-30 | ¥35m |
| —segment total | segment profit | 2021-01-01 → 2021-09-30 | ¥2.0bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 716
| Item | Context | Value | Unit |
|---|---|---|---|
| Put option for non controlling interest ss IFRS | Prior1YTDDuration | 3898338000 | JPY |
| Other ss IFRS | Prior1YTDDuration_EquityAttributableToOwnersOfParentIFRSMember | 207000 | JPY |
| Other ss IFRS | Prior1YTDDuration_NonControllingInterestsIFRSMember | - | JPY |
| Other ss IFRS | Prior1YTDDuration | 207000 | JPY |
| Total transactions with owners IFRS | Prior1YTDDuration_EquityAttributableToOwnersOfParentIFRSMember | 5288461000 | JPY |
| Total transactions with owners IFRS | Prior1YTDDuration_NonControllingInterestsIFRSMember | -562390000 | JPY |
| Total transactions with owners IFRS | Prior1YTDDuration | 4726071000 | JPY |
| Equity IFRS | Prior1QuarterInstant_EquityAttributableToOwnersOfParentIFRSMember | 18502426000 | JPY |
| Equity IFRS | Prior1QuarterInstant_NonControllingInterestsIFRSMember | 926654000 | JPY |
| Equity IFRS | Prior1QuarterInstant | 19429080000 | JPY |
| Equity IFRS | Prior1YearInstant_ShareCapitalIFRSMember | 10884332000 | JPY |
| Equity IFRS | Prior1YearInstant_CapitalSurplusIFRSMember | 6224649000 | JPY |
| Equity IFRS | Prior1YearInstant_TreasurySharesIFRSMember | -645000 | JPY |
| Equity IFRS | Prior1YearInstant_RetainedEarningsIFRSMember | 307535000 | JPY |
| Equity IFRS | Prior1YearInstant_ShareAcquisitionRightsIFRSMember | 543445000 | JPY |
| Equity IFRS | Prior1YearInstant_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember | 900992000 | JPY |
| Equity IFRS | Prior1YearInstant_OtherComponentsOfEquityIFRSMember | 1444437000 | JPY |
| Profit loss IFRS | CurrentYTDDuration_ShareCapitalIFRSMember | - | JPY |
| Profit loss IFRS | CurrentYTDDuration_CapitalSurplusIFRSMember | - | JPY |
| Profit loss IFRS | CurrentYTDDuration_TreasurySharesIFRSMember | - | JPY |
| Profit loss IFRS | CurrentYTDDuration_RetainedEarningsIFRSMember | 1076065000 | JPY |
| Profit loss IFRS | CurrentYTDDuration_ShareAcquisitionRightsIFRSMember | - | JPY |
| Profit loss IFRS | CurrentYTDDuration_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember | - | JPY |
| Profit loss IFRS | CurrentYTDDuration_OtherComponentsOfEquityIFRSMember | - | JPY |
| Other comprehensive income IFRS | CurrentYTDDuration_ShareCapitalIFRSMember | - | JPY |
| Other comprehensive income IFRS | CurrentYTDDuration_CapitalSurplusIFRSMember | - | JPY |
| Other comprehensive income IFRS | CurrentYTDDuration_TreasurySharesIFRSMember | - | JPY |
| Other comprehensive income IFRS | CurrentYTDDuration_RetainedEarningsIFRSMember | - | JPY |
| Other comprehensive income IFRS | CurrentYTDDuration_ShareAcquisitionRightsIFRSMember | - | JPY |
| Other comprehensive income IFRS | CurrentYTDDuration_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember | 2757385000 | JPY |
| Other comprehensive income IFRS | CurrentYTDDuration_OtherComponentsOfEquityIFRSMember | 2757385000 | JPY |
| Comprehensive income IFRS | CurrentYTDDuration_ShareCapitalIFRSMember | - | JPY |
| Comprehensive income IFRS | CurrentYTDDuration_CapitalSurplusIFRSMember | - | JPY |
| Comprehensive income IFRS | CurrentYTDDuration_TreasurySharesIFRSMember | - | JPY |
| Comprehensive income IFRS | CurrentYTDDuration_RetainedEarningsIFRSMember | 1076065000 | JPY |
| Comprehensive income IFRS | CurrentYTDDuration_ShareAcquisitionRightsIFRSMember | - | JPY |
| Comprehensive income IFRS | CurrentYTDDuration_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember | 2757385000 | JPY |
| Comprehensive income IFRS | CurrentYTDDuration_OtherComponentsOfEquityIFRSMember | 2757385000 | JPY |
| Issuance of new shares ss IFRS | CurrentYTDDuration_ShareCapitalIFRSMember | 6858000 | JPY |
| Issuance of new shares ss IFRS | CurrentYTDDuration_CapitalSurplusIFRSMember | 6858000 | JPY |
| Issuance of new shares ss IFRS | CurrentYTDDuration_TreasurySharesIFRSMember | - | JPY |
| Issuance of new shares ss IFRS | CurrentYTDDuration_RetainedEarningsIFRSMember | - | JPY |
| Issuance of new shares ss IFRS | CurrentYTDDuration_ShareAcquisitionRightsIFRSMember | - | JPY |
| Issuance of new shares ss IFRS | CurrentYTDDuration_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember | - | JPY |
| Issuance of new shares ss IFRS | CurrentYTDDuration_OtherComponentsOfEquityIFRSMember | - | JPY |
| Share based payment transactions ss IFRS | CurrentYTDDuration_ShareCapitalIFRSMember | - | JPY |
| Share based payment transactions ss IFRS | CurrentYTDDuration_CapitalSurplusIFRSMember | - | JPY |
| Share based payment transactions ss IFRS | CurrentYTDDuration_TreasurySharesIFRSMember | - | JPY |
| Share based payment transactions ss IFRS | CurrentYTDDuration_RetainedEarningsIFRSMember | - | JPY |
| Share based payment transactions ss IFRS | CurrentYTDDuration_ShareAcquisitionRightsIFRSMember | 200651000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 16 of 16 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |